參考文獻(xiàn)/References:
[1] 陳旭,胡樂(lè),樓龍泉,等.乳腺癌患者早期骨轉(zhuǎn)移的危險(xiǎn)因素分析[J].中華乳腺病雜志,2020,14(2):98-103.[2] 滕小艷,魏麗榮,夏前林,等.肺癌骨轉(zhuǎn)移分子機(jī)制及相關(guān)分子標(biāo)志物臨床意義的研究進(jìn)展[J].國(guó)際骨科學(xué)雜志,2020,41(3):138-142.[3] 王磊,孫俊英.血清NTx和ICTP檢測(cè)在乳腺癌骨轉(zhuǎn)移中的臨床意義[J].陜西醫(yī)學(xué)雜志,2014,43(2):208-211.[4] Lang J L, Zhao Q, He Y D, et al.Bone turnover markers and novel biomarkers in lung cancer bone metastases [J]. Biomarkers, 2018, 23(4): 1-33.[5] 劉康其,周海中.放射性藥物聯(lián)合雙膦酸鹽類(lèi)藥物治療腫瘤骨轉(zhuǎn)移研究現(xiàn)狀[J].國(guó)際放射醫(yī)學(xué)核醫(yī)學(xué)雜志,2019,43(2):166-170.[6] Xin Y, Han B H, Wu J, et al.Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases [J]. Chin J Lung Cancer, 2010, 13(10): 947-53.[7] 張輝,張陽(yáng).惡性腫瘤骨轉(zhuǎn)移性疾病治療的進(jìn)展[J].中國(guó)醫(yī)療前沿,2010,5(5):14,16.[8] Jung K, Lein M.Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis [J]. Biochim Biophys Acta, 2014, 18(46): 425-438.[9] Joerger M, Huober J.Diagnostic and prognostic use of bone turnover markers [J]. Cancer Res, 2012, 192:197-223.[10] Ottewell P D.Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone [J]. Endocr-Relat Cancer, 2014, 21(5): 769-781.[11] Tamiya M, Suzuki H, Kobayashi M, et al.Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer [J]. Med Oncol, 2015, 29(1): 215-218.[12] 李淼沅,袁潤(rùn)強(qiáng),陳業(yè)輝.前列腺癌并骨轉(zhuǎn)移的治療新進(jìn)展[J].中華腔鏡泌尿外科雜志,2018,12(2):73-75.[13] 楊峻峰,王劍松.前列腺癌骨轉(zhuǎn)移治療的新進(jìn)展[J].現(xiàn)代泌尿生殖腫瘤雜志,2012,4(2):121-124.[14] 趙瑞,李鳴.Ⅰ型膠原交聯(lián)氨基末端肽在前列腺癌骨轉(zhuǎn)移診斷中的意義[J].現(xiàn)代泌尿生殖腫瘤雜志,2010,2(5):234-236.[15] 陳昊,何屹,候巖松,等.血清骨性標(biāo)記物NTx和BALP與前列腺癌骨轉(zhuǎn)移的關(guān)系及臨床意義[J].臨床腫瘤學(xué)雜志,2016,21(12):1111-1113.[16] 張作艷,關(guān)泉林,趙達(dá).骨代謝標(biāo)記物在實(shí)體瘤骨轉(zhuǎn)移診斷中的臨床意義[J].實(shí)用癌癥雜志,2013,28(5):486-488.[17] 鄧立春,姜藻,沈偉生,等.血清NTx、BSP和PSA檢測(cè)在前列腺癌骨轉(zhuǎn)移診斷中的意義[J].現(xiàn)代醫(yī)學(xué),2013,41(8):546-549.[18] Kong P, Yan J, Liu D, et al.Skeletal-related events and overall survival of patients with bone metastasis from non small cell lung cancer-a retrospective analysis [J]. Medicine(Baltimore), 2017, 96(51): e9327.[19] Wang H, Zhang Y, Zhu H, et al.Risk factors for bone metastasis in completely resected non-small-cell lung cancer[J]. Future Oncol, 2017, 13(8): 695-704.[20] 高志棣,考軍,周文麗,等.UNTX水平檢測(cè)在監(jiān)測(cè)肺癌骨轉(zhuǎn)移中的價(jià)值[J].實(shí)用癌癥雜志,2007,22(2):167-170.[21] 喬丹,王智煜,文孝婷,等.血清-NTx對(duì)肺癌、乳腺癌患者診斷骨轉(zhuǎn)移及預(yù)后評(píng)價(jià)價(jià)值的Meta分析[J].臨床腫瘤學(xué)雜志,2015(3):212-216.[22] Liu B, Zhao Y, Yuan J, et al.Elevated n-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: a meta-analysis [J]. PLoS One, 2017, 12(11): e0187860.[23] Huang J D, Gu T J, Ying J.A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer [J]. Int J Clin Oncol, 2017, 22(6): 1015-1025.[24] 張世強(qiáng),陳冬波,王保慶,等.肺癌患者血清NTx、ICTP和BAP水平與骨轉(zhuǎn)移的相關(guān)性研究[J].臨床腫瘤學(xué)雜志,2011,16(6):534-537.[25] 吳瓊,馬海洋,張明明,等.多因素聯(lián)合對(duì)于肺癌骨轉(zhuǎn)移的診斷價(jià)值[J].中國(guó)醫(yī)學(xué)導(dǎo)報(bào),2018,15(16):55-58.[26] Wu C J, Ma L X, Liu J J, et al.Clinical significance of combined detection of urine NTX and serum ICTP for breast cancer patients with bone metastases [J]. Chin J Oncol, 2016, 38(9): 693-697.